NGN-101 clinical trials

Gene Therapy Study for Children With CLN5 Batten Disease

This study is looking at a new gene therapy called NGN-101 for children aged 3 to 9 with CLN5 Batten disease. It aims to check if the treatment is safe and if it helps improve their health. Children will be followed for 5 years.